Organization (Other)
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
ClinicalTrials.gov lists PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor of 43 trials. It has 28 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers PersonGen BioTherapeutics (Suzhou) Co., Ltd.: 43 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (51)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lymphoma | 13 |
| Lymphoma, Non-Hodgkin | 12 |
| Leukemia, Myeloid, Acute | 10 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 |
| Lymphoma, B-Cell | 5 |
Showing 5 of 51 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 8 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 5 |
| 2021 | 8 |
| 2020 | 4 |
| 2019 | 6 |
| 2018 | 3 |
| 2016 | 6 |
Showing 10 of 11 years.
Prediction, not a registry value: median of 25 months from start to primary completion across 12 trials still running at the 2026-10-09 snapshot. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (28)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| LV009 Injection | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | 1 |
| LV009 Injection | Lymphoma, Non-Hodgkin | Phase 1 | 1 |
| LV009 Injection | Lymphoma | Phase 1 | 1 |
| B7-H3 target, CAR gene modified gdT cell injection | Leukemia, Myeloid, Acute | Phase 1 | 1 |
| UTAA91 injection | Scleroderma, Systemic | Early 1 | 2 |
Showing 5 of 28 active programs.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| CYCLOPHOSPHAMIDE | 1 |
| FLUDARABINE | 1 |
Journals published in (7)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| American journal of clinical pathology | 1 |
| BMC pulmonary medicine | 1 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 1 |
| Cytometry. Part B, Clinical cytometry | 1 |
| Experimental hematology & oncology | 1 |
Showing 5 of 7 journals.
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| The First People's Hospital of Hefei | Co sponsors trial with | 6 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Co sponsors trial with | 2 |
Latest dated events (47)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 47 events.
Biomarker capability evidence (140)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| CD19 | Trial sponsor | Named in trial inclusion criteria |
| CD19 | Trial sponsor | Named in trial inclusion criteria |
| CD19 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 140 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.